Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Core Viewpoint - Autolus Therapeutics plc is set to release its fourth quarter and full year 2025 financial results and operational highlights on March 27, 2026, before the U.S. market opens [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast scheduled for 8:30am EDT / 12:30pm GMT on the same day [2] - Participants are required to pre-register to receive dial-in numbers and a personal PIN for accessing the conference call [2] Group 2: Company Overview - Autolus Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary and modular T cell programming technologies to create targeted and controlled T cell therapies [3] - Autolus has a marketed therapy named AUCATZYL and a pipeline of candidates aimed at treating hematological malignancies, solid tumors, and autoimmune diseases [3]